Avadel Pharmaceuticals plc Financials

Market Capitalization $765.1 Million as of Jan. 1, 2025

Valuations Metrics as of Jan. 25, 2025

Trailing PE	-3.92
Forward PE	11.68
Price to Sales TTM	$5.54
Price to Book MRQ	$10.25
Enterprise to Revenue	5.34
Enterprise to EBITDA	-11.90

Financial Reports as of Sep. 30, 2024

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2024-09-30
Profit Margin	-52.53%
Operating Margin	-0.65%
Return on Assets TTM	-22.14%
Return on Equity TTM	-78.54%

Income Statement

Revenue TTM	$138,160,000
Revenue per Share TTM	$1.48
Quarterly Revenue Growth	613.20%
Gross Profit TTM	$127,002,000
EBITDA	$-62,007,000
Net Income to Common TTM	$-72,575,000
Diluted EPS TTM	$-0.75
Quarterly Earnings Growth YoY	613.22%

Balance Sheet

Total Cash MRQ	$65,807,000
Total Cash per Share MRQ	$0.68
Total Debt MRQ	$
Total Debt to Equity MRQ	51.24
Current Ratio MRQ	2.97
Book Value per Share MRQ	$0.78

Cash Flow

Operating Cash Flow TTM	$-82,809,000
Levered Free Cash Flow TTM	$-58,922,500

AVDL Stock Info as of Jan. 25, 2025

Stock Statistics

Shares Outstanding	96,361,504
Float Shares	83,305,505
Avg 10 Volume	2,444,840
Avg 30 Volume	None
Shares Short	11,770,961
Short Ratio	10.87
Short % of Shares	13.97%
% Held by Insiders	4.78%
% Held by Institutions	80.71%

Stock Price Summary

Beta
Fifty Two Week Low	$7.39
Fifty Two Week High	$19.09
Fifty Two Week Change	-85.99%
Day 50 MA	$10.47
Day 200 MA	$14.11

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date